

Special Editorial



Received: Jan 9, 2025

Accepted: Jan 13, 2025

Published online: Jan 18, 2025

Correspondence to

In-Kyung Jeong

Division of Endocrinology and Metabolism,
Department of Internal Medicine, Kyung Hee
University Hospital at Gangdong, Kyung Hee
University School of Medicine, 892 Dongnam-
ro, Gangdong-gu, Seoul 05278, Korea.
Email: jik1016@naver.com
jik1016@khu.ac.kr

© 2025 The Korean Society of Lipid and
Atherosclerosis.

This is an Open Access article distributed
under the terms of the Creative Commons
Attribution Non-Commercial License (<https://creativecommons.org/licenses/by-nc/4.0/>)
which permits unrestricted non-commercial
use, distribution, and reproduction in any
medium, provided the original work is properly
cited.

ORCID iDs

In-Kyung Jeong
<https://orcid.org/0000-0001-7857-546X>

Funding

None.

Conflict of Interest

In-Kyung Jeong has been Editor-in-Chief
of the *Journal of Lipid and Atherosclerosis*
since 2025. However, she was not involved
in the peer reviewer selection, evaluation, or
decision-making process of this article. No
other potential conflicts of interest relevant to
this article were reported.

Data Availability Statement

Not Applicable.

<https://e-jla.org>

Journal of Lipid and Atherosclerosis in 2025: From Excellence to Eminence

In-Kyung Jeong , Editor-in-Chief

Division of Endocrinology and Metabolism, Department of Internal Medicine, Kyung Hee University
Hospital at Gangdong, Kyung Hee University School of Medicine, Seoul, Korea

It is a great honor for me to be appointed as the Editor-in-Chief of *Journal of Lipid and Atherosclerosis (JLA)*. This is a significant responsibility, and I will dedicate myself to upholding the high standards of *JLA* as a leading journal.

JLA is the official journal of the Korean Society of Lipid and Atherosclerosis (KSoLA). KSoLA was established in 2001 through the merger of the Korean Society of Lipidology, founded in 1990, and the Korean Society of Atherosclerosis, founded in 1998. It is an academic organization where experts from various fields, including clinical medicine (endocrinology and metabolism, cardiology, neurology), basic sciences (biochemistry, molecular biology, immunology), food and nutrition, preventive medicine, and epidemiology, actively engage in research. KSoLA's mission is to advance the study of lipids and atherosclerosis and contribute to the promotion of public health and well-being.

Regarding the history of KSoLA's official journal, the '*Korean Journal of Lipidology*,' first published in 1991 by the Korean Society of Lipidology, was succeeded in 2001 by the '*Korean Journal of Lipid and Atherosclerosis*.' In 2012, the journal was relaunched under its current title, '*Journal of Lipid and Atherosclerosis*.' It was indexed in KoreaMed in 2013, included in the Korea Citation Index (KCI) in 2017, and transitioned to an English-language journal in 2019 to establish itself as an international academic journal. Since 2020, it has been indexed in Scopus and PubMed Central, marking its growth as a global academic publication. The journal aspires to achieve SCIE indexing in the near future.

JLA is an international, peer-reviewed, open-access journal affiliated with KSoLA, focusing on lipid metabolism and atherosclerosis. The journal's scope encompasses basic, translational, and clinical research in lipid metabolism, atherosclerosis, and cardiovascular diseases, offering a robust perspective on the Asia-Pacific population. Additionally, *JLA* features methodological reviews to provide readers with educational foundations and practical insights for research in these fields. By addressing critical and emerging clinical issues within a focused geographic and scientific context, the journal contributes significantly to advancing knowledge and clinical practice.

JLA has consistently provided readers with informative, valuable, and up-to-date research. A notable example is the report titled Dyslipidemia Fact Sheet in South Korea, 2022, published in September 2023.¹ This study revealed that in 2020, the crude prevalence of hypercholesterolemia (defined as total cholesterol ≥ 240 mg/dL or the use of a lipid-lowering

drug) in South Korea was 24%, and the age-standardized prevalence of hypercholesterolemia more than doubled from 2007 to 2020. Despite the rising prevalence of dyslipidemia, the treatment rates remain low. *JLA* has also published significant treatment guidelines, including those for dyslipidemia,² familial hypercholesterolemia,³ dyslipidemia associated with type 2 diabetes,⁴ and secondary dyslipidemia.⁵ The journal has featured papers on novel treatments and molecular mechanisms related to dyslipidemia,^{6,7} further enriching the scientific discourse. To increase global accessibility, video abstracts of published papers are made available on YouTube, supporting researchers worldwide.

Numerous individuals, including esteemed KSoLA members, authors, reviewers, and editors have collaborated to make *JLA* the best it can be. I would like to especially thank for the efforts and devotion to our previous members; KSoLA president, Ick-Mo Chung, MD, PhD; chairman and board of directors of KSoLA, Jaetaek Kim, MD, PhD; editors-in-chief, Hyun Kang; deputy editors, Nam Hoon Kim, Hyun-Jin Kim, Jeong-Min Kim, Young-Kook Kim, Yong Seek Park; and other editorial team members. Additionally, on behalf of the editorial board of the *JLA*, I extend my deepest gratitude to the outstanding reviewers for their invaluable contributions.

JLA will continue to explore new perspectives in epidemiology, pathophysiology, treatment approaches, nutrition, medications, and innovative technologies for the management of dyslipidemia and atherosclerosis. *JLA* will also strive to advance from excellence to eminence in the field of lipid and atherosclerosis.

REFERENCES

1. Jin ES, Shim JS, Kim SE, Bae JH, Kang S, Won JC, et al. Dyslipidemia Fact Sheet in South Korea, 2022. *J Lipid Atheroscler* 2023;12:237-251. [PUBMED](#) | [CROSSREF](#)
2. Rhee EJ, Kim HC, Kim JH, Lee EY, Kim BJ, Kim EM, et al. 2018 guidelines for the management of dyslipidemia in Korea. *J Lipid Atheroscler* 2019;8:78-131. [PUBMED](#) | [CROSSREF](#)
3. Lee CJ, Yoon M, Kang HJ, Kim BJ, Choi SH, Jeong IK, et al. 2022 consensus statement on the management of familial hypercholesterolemia in Korea. *J Lipid Atheroscler* 2022;11:213-228. [PUBMED](#) | [CROSSREF](#)
4. Yang YS, Kim HL, Kim SH, Moon MK; Committee of Clinical Practice Guideline, Korean Diabetes Association and Clinical Practice Guideline Committee, Korean Society of Lipid and Atherosclerosis. Lipid management in Korean people with type 2 diabetes mellitus: Korean Diabetes Association and Korean Society of Lipid and Atherosclerosis Consensus Statement. *J Lipid Atheroscler* 2023;12:12-22. [PUBMED](#) | [CROSSREF](#)
5. Won H, Bae JH, Lim H, Kang M, Kim M, Lee SH, et al. 2024 KSoLA consensus on secondary dyslipidemia. *J Lipid Atheroscler* 2024;13:215-231. [PUBMED](#) | [CROSSREF](#)
6. Kim JY, Kim NH. New therapeutic approaches to the treatment of dyslipidemia 1: ApoC-III and ANGPTL3. *J Lipid Atheroscler* 2023;12:23-36. [PUBMED](#) | [CROSSREF](#)
7. Poznyak AV, Sukhorukov VN, Popov MA, Chegodaev YS, Postnov AY, Orekhov AN. Mechanisms of the Wnt pathways as a potential target pathway in atherosclerosis. *J Lipid Atheroscler* 2023;12:223-236. [PUBMED](#) | [CROSSREF](#)